ストックスクリーナーアプリを入手
68.57
2.22%
1.49
アフターアワーズ：
68.57
前日終値:
$67.08
開ける：
$67
24時間の取引高:
503.13K
Relative Volume:
0.65
時価総額：
$3.30B
収益：
-
当期純損益:
$-86.97M
株価収益率:
-28.35
EPS:
-2.4189
ネットキャッシュフロー:
$-81.88M
1週間 パフォーマンス:
+1.11%
1か月 パフォーマンス:
+21.17%
6か月 パフォーマンス:
+80.02%
1年 パフォーマンス:
+419.08%
1日の値動き範囲:
$65.01
$68.84
1週間の範囲:
$65.01
$68.84
52週間の値動き範囲:
$9.63
$72.64
Mbx Biosciences Inc Stock (MBX) Company Profile
Compare MBX vs VRTX, REGN, ARGX, RVMD, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MBX
Mbx Biosciences Inc
|
68.57 | 3.23B | 0 | -86.97M | -81.88M | -2.4189 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Mbx Biosciences Inc Stock (MBX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-28 | 開始されました | Barclays | Overweight |
| 2025-12-04 | 開始されました | Goldman | Sell |
| 2025-11-04 | 開始されました | TD Cowen | Buy |
| 2025-10-15 | 開始されました | Truist | Buy |
| 2025-08-15 | 再開されました | Jefferies | Buy |
| 2025-08-05 | 開始されました | Mizuho | Outperform |
| 2025-07-16 | 開始されました | Oppenheimer | Outperform |
| 2025-04-10 | 開始されました | Citizens JMP | Mkt Outperform |
| 2024-10-08 | 開始されました | Guggenheim | Buy |
| 2024-10-08 | 開始されました | JP Morgan | Overweight |
| 2024-10-08 | 開始されました | Jefferies | Buy |
| 2024-10-08 | 開始されました | Stifel | Buy |
すべてを表示
Mbx Biosciences Inc (MBX) 最新ニュース
California State Teachers Retirement System Purchases 21,011 Shares of MBX Biosciences, Inc. $MBX - marketbeat.com
Deep Track Capital reports 3.64% MBX Biosciences (MBX) stake in 13G/A - Stock Titan
Stifel Maintains MBX Biosciences(MBX.US) With Buy Rating, Raises Target Price to $70 - moomoo.com
MBX Biosciences (MBX) Short Interest & Short Float | Updated Aug 2026 - marketbeat.com
Frazier funds detail 10.8% MBX Biosciences stake (MBX) in ownership update - Stock Titan
OrbiMed trims MBX Biosciences (MBX) position to 6.4% after share sales - Stock Titan
Truist Adjusts Price Target on MBX Biosciences to $88 From $70, Maintains Buy Rating - moomoo.com
MBX Biosciences, Inc. $MBX Stock Holdings Raised by The Manufacturers Life Insurance Company - marketbeat.com
LifeSci Capital Maintains MBX Biosciences(MBX.US) With Buy Rating, Maintains Target Price $121 - moomoo.com
MBX Biosciences (NASDAQ:MBX) Lowered to "Sell" Rating by Wall Street Zen - marketbeat.com
Mizuho Securities Maintains MBX Biosciences(MBX.US) With Buy Rating, Maintains Target Price $91 - Moomoo
MBX SWOT Analysis: Financial Challenges and Growth Potential Rev - GuruFocus
Barclays Maintains MBX Biosciences(MBX.US) With Buy Rating, Raises Target Price to $88 - moomoo.com
MBX Biosciences (MBX) Stock Analysis: Strong Buy Ratings and Significant Upside Potential - DirectorsTalk Interviews
MBX Biosciences, Inc. Stock 12‑Month Price Target Raised to $84.8, Implies 26% Upside - TradingView
MBX Biosciences Shares Lower After Q2 Loss Widens - marketscreener.com
MBX Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
MBX Biosciences, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Earnings Flash (MBX) MBX Biosciences Posts Q2 Net Loss $0.78 a Share, vs. FactSet Est of $0.63 Loss - marketscreener.com
MBX Biosciences posts Q2 loss, advances obesity pipeline By Investing.com - Investing.com South Africa
MBX Biosciences posts Q2 loss, advances obesity pipeline - Investing.com
MBX Biosciences Reports Second Quarter 2026 Financial Results and Corporate Highlights - The Manila Times
MBX Biosciences posts $37.1 million Q2 net loss - Quiver Quantitative
Earnings Flash (MBX) MBX Biosciences Posts Q2 Net Loss $0.78 a Share, Vs. FactSet Est of $0.63 Loss - Moomoo
MBX Biosciences 2Q 2026: Net loss $(37.1M), EPS $(0.78) — 10-Q Summary - TradingView
MBX: Q2 net loss increased to $37.1M as R&D spending rose; cash reserves support operations into 2029 - TradingView
MBX Biosciences (Nasdaq: MBX) widens Q2 loss but holds $418.6M cash - Stock Titan
MBX Biosciences (MBX) Earnings Date and Reports 2026 - marketbeat.com
Insider Selling: MBX Biosciences (NASDAQ:MBX) Insider Sells $24,334.90 in Stock - MarketBeat
MBX Biosciences (MBX) CMO sells 370 shares to cover RSU taxes - Stock Titan
MBX: Advancing precision peptide therapies for endocrine and obesity indications with strong clinical momentum - TradingView
MBX Q2'26 Earnings: EPS estimate is (0.63) USD - TradingView
MBX Biosciences (NASDAQ:MBX) Reaches New 52-Week HighStill a Buy? - marketbeat.com
Mbx Biosciences stock hits all-time high of 69.5 USD By Investing.com - Investing.com India
MBX (MBX) affiliate plans to sell 936 vested common shares after prior sale - Stock Titan
Salomon Azoulay plans 370-share sale of MBX (NASDAQ: MBX) - Stock Titan
Mbx Biosciences stock hits all-time high of 69.5 USD - Investing.com
MBX Biosciences, Inc. (MBX) awards CFO 130,000 options and 28,000 RSUs - Stock Titan
MBX Biosciences, Inc. (MBX) grants CEO major option and RSU awards - Stock Titan
Swiss National Bank Invests $1.32 Million in MBX Biosciences, Inc. $MBX - marketbeat.com
MBX Biosciences, Inc. $MBX Shares Purchased by Stempoint Capital LP - MarketBeat
MBX Biosciences (NASDAQ:MBX) Sets New 52-Week High on Analyst Upgrade - marketbeat.com
MBX Biosciences | SCHEDULE 13G: Others - moomoo.com
EcoR1 Capital LLC Decreases Stock Position in MBX Biosciences, Inc. $MBX - MarketBeat
Wall Street Zen Upgrades MBX Biosciences (NASDAQ:MBX) to Hold - marketbeat.com
MBX Biosciences Inc (MBX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
MBX Biosciences Inc (MBX) Institutional Confidence - TradingKey
MBX Biosciences, Inc. $MBX is Orbimed Advisors LLC's 10th Largest Position - MarketBeat
MBX Biosciences Inc (MBX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
MBX Biosciences Market Sentiment - Benzinga España
MBX Biosciences Inc (MBX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Mbx Biosciences Inc (MBX) 財務データ
収益
当期純利益
現金流量
EPS
0.52%
0.07%
大文字化:
|
ボリューム (24 時間):